Every material Form 8-K AtriCure, Inc. has filed with the SEC since May 19, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
AtriCure reported third quarter 2026 revenue of $154.5 million, up 15.0% from a year earlier, and net income of $4.1 million, compared with a net loss of $267 thousand in the same quarter of 2025. The company also projected full year 2026 revenue of approximately $606 million to $610 million and adjusted EBITDA of approximately $91 million to $94 million, which gives shareholders updated figures for the year.
Q3 2026 revenue was $154.5 million, up 15.0%; U.S. revenue rose 17.1% to $128.0 million.
Net income was $4.1 million, or $0.08 per diluted share, versus a loss of $0.01 per share a year earlier.
Adjusted EBITDA was $26.8 million, up 51% from $17.8 million in Q3 2025.
Full year 2026 revenue is now projected at approximately $606 million to $610 million; the filing does not state the prior projection.
AtriCure reported second quarter 2026 revenue of $153.6 million, up 12.8% from a year earlier, and net income of $9.0 million, compared with a net loss of $6.2 million in the same quarter of 2025. The company also issued full-year 2026 guidance of $602 million to $610 million in revenue and $0.05 to $0.13 in net income per share, which shareholders can compare with future results.
Q2 2026 revenue was $153.6 million, up from $136.1 million in Q2 2025; U.S. revenue rose 13.6% to $125.6 million.
Net income was $9.0 million, or $0.18 per diluted share, versus a net loss of $6.2 million, or $0.13 per share, a year earlier.
Adjusted EBITDA was $27.3 million, an increase of $11.9 million or 78% from Q2 2025.
2026 guidance: revenue of approximately $602 million to $610 million and net income per share of $0.05 to $0.13.
At its May 18, 2026 annual meeting, AtriCure stockholders approved raising the share reserve of the 2023 Stock Incentive Plan from 4,500,000 to 6,000,000 shares, and approved a 750,000-share increase to the 2018 Employee Stock Purchase Plan. All nine director nominees were elected, and stockholders ratified Deloitte & Touche LLP as auditor for fiscal 2026. The votes give the company additional equity capacity for employee and director compensation, which can dilute existing shareholders.
Stockholders approved a 1,500,000-share increase to the 2023 Stock Incentive Plan, from 4,500,000 to 6,000,000 shares.
Stockholders approved a 750,000-share increase to the 2018 Employee Stock Purchase Plan (42,064,798 for, 109,893 against).
All nine director nominees were elected to one-year terms expiring at the 2027 annual meeting.
Deloitte & Touche LLP was ratified as independent auditor for fiscal year ending December 31, 2026 (43,617,566 for, 2,327,505 against).
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every AtriCure, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →